Radiopharm Theranostics Limited (AU:RAD) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Radiopharm Theranostics has successfully completed preclinical studies for its innovative prostate cancer treatment, RAD 402, showing promising safety and biodistribution results. The company plans to begin Phase I clinical trials in the second half of 2025, aiming to advance this next-generation radiotherapeutic to address unmet needs in advanced prostate cancer. This development signifies a potential breakthrough in cancer treatment, with RAD 402 targeting prostate-specific antigens using the novel isotope Terbium-161.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.